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1. Introduction
Apoptosis is programmed cell death triggered by various 
stimuli from outside or inside the cell, such as ligation 
of cell surface receptors, treatment with cytotoxic drugs, 
or irradiation and it results in transcriptionally regulated 
activation of a number of regulatory proteins (Blank and 
Shiloh, 2007). Apoptosis is characterized by exposure 
of phosphatidylserine on the plasma membrane outer 
leaflet, membrane blebbing, cellular shrinkage, chromatin 
condensation, and fragmentation of nuclear DNA, leading 
to formation of apoptotic bodies (Blagosklonny, 2000; 
Baumann et al., 2002).
T cells constitute a vital branch of cell-mediated 
immunity and homeostasis of the immune response 
is sustained through a balance between proliferation 
and apoptosis of T cells. A wealth of information has 
accumulated over the past two decades about the 
transcriptional regulation of genes mediating apoptosis 
in T cells. The recent discovery of small RNAs, however, 
suggests that posttranscriptional gene regulatory networks 
might have prominent effects on modulation of apoptotic 
pathways of T cells (Lodish et al., 2008; O’Connell et al., 
2010). MicroRNAs (miRNAs), a type of those small RNAs, 
are noncoding small RNAs of about 19–25 nucleotides 
in length, which are transcribed by RNA polymerase II 
(Bartel, 2004, 2009). Followed by nuclear processing by 
Drosha and cytoplasmic processing by Dicer, the mature 
miRNA strand negatively regulates gene expression by 
translational inhibition or destabilization of mRNAs 
(Miska, 2005; Lawrie, 2007; Stefani and Slack, 2008). MiR-
14 and bantam were the first members of miRNAs shown 
to modulate apoptotic functions in Drosophila (Brennecke 
et al., 2003; Xu et al., 2003). Over the past few years, a clear 
link has been established between apoptosis and miRNAs 
(Su et al., 2015), particularly in cancer development 
(Kumar et al., 2007; Marcucci et al., 2011).
Besides the significance of miRNAs in T-cell functions, 
miRNA-mediated T-cell apoptosis has also been associated 
with oncogenic miRNAs in leukemogenesis (Calin et al., 
2009; Pekarsky et al., 2009; Chen et al., 2010). In fact, 
miRNA profiling studies particularly on cancerous tissues 
have clearly shown that each leukemia type (for instance, 
CLL vs. ALL) possesses a prominent miRNA expression 
signature (Zanette et al., 2007). Additional studies showed 
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that these miRNAs regulate the expression of apoptotic or 
antiapoptotic mRNAs (Mott et al., 2007; Xiao et al., 2008; 
Akao et al., 2009).
Although the use of cell lines has led to the identification 
of a number of dysregulated miRNAs involved in 
apoptosis and/or leukemogenesis (Li et al., 2013; Yamada 
et al., 2014; Zhou et al., 2014; Fan et al., 2016), cellular 
heterogeneity associated with cancerous tissues requires 
careful interpretation of the data acquired from human 
studies. Cellular heterogeneity is also an important issue 
that needs to be taken into account while interpreting 
the data collected from cell lines. It is well documented 
that cells use cellular heterogeneity to function properly 
and survive (Benchaouir, 2004; Stockholm et al., 2007; 
Walling et al., 2012). Jurkat cells were also reported to be 
heterogeneous as sublines from the same clones displayed 
different cellular morphologies and growth patterns 
(Snow and Judd, 2009). Although miRNA heterogeneity 
is known to exist across different cell lines that originate 
from the same cancer type (Lu et al., 2015), the potential 
for differential miRNA expression across the cells in the 
same cell line has not been reported before. To identify 
miRNAs that regulate apoptosis in Jurkat cells and also to 
test the effect of cellular heterogeneity on drug response 
and miRNA expression profiles, we triggered apoptosis 
in Jurkat cells with camptothecin, an inhibitor of DNA 
topoisomerase I and a potent inducer of apoptosis (Li 
and Liu, 2001; Pommier et al., 2003). Following the drug 
treatment, we sorted the apoptotic subpopulation (as 
defined by Annexin V positivity) from the nonapoptotic 
subpopulation by magnetic beads. Deep sequencing of 
small RNAs isolated from each subpopulation revealed 
that each subpopulation possessed a distinct miRNA 
expression signature that might be associated with a 
population-specific apoptotic response. 
2. Materials and methods
2.1. Cell culture, drug treatment, and transfection
Jurkat human leukemic T cells (American Type Culture 
Collection clone E6.1) were maintained in RPMI 1640 
(GIBCO) supplemented with 2 mM L-glutamine, 10% 
fetal bovine serum (GIBCO), and 100 U penicillin/100 
µg streptomycin (Biochrom AG) in an atmosphere of 5% 
CO2 at 37 °C. Cells (n = 106) were treated with different 
concentrations of camptothecin (Sigma) and incubated at 
37 °C and 5% CO2 to determine the dose kinetics. Cells in 
both the treatment and control groups were labeled with 
PE-conjugated Annexin V and 7-AAD (BD Pharmingen) 
and analyzed by flow cytometry (BD FACSArray) to identify 
stages of apoptosis. Cells that were Annexin V-positive 
but 7-AAD-negative were defined as early apoptotic ones. 
Annexin-V-positive cells were then separated by Annexin 
V Microbead Kit (Miltenyi Biotech) according to the 
manufacturer’s instructions. Four fractions were obtained 
as follows: untreated Annexin-negative (JNN), untreated 
Annexin-positive (JNP), treated Annexin-positive (JAP), 
and treated Annexin-negative (JAN) cells. Because 
sufficient cells could not be obtained from the JNP cells, 
they were excluded from the study.
2.2. Total RNA isolation and deep sequencing
Total RNA was isolated with the mirVana miRNA Isolation 
Kit (Ambion) according to the manufacturer’s instructions. 
Total RNA samples were treated with the TurboDNase 
DNA-free Kit (Ambion) to remove traces of genomic 
DNA contamination. RNA integrity was determined by a 
bioanalyzer (Agilent 2100) using the RNA 6000 Nano Kit 
(average RIN: ~9–10). 
Three replicates from JNN, JAP, and JAN cells were 
mixed in equal amounts and sequenced using the 
Illumina Genome Analyzer by Fasteris (Switzerland). 
The fragments missing either adaptor were excluded 
from further analyses. The adaptor sequences of 15–29 
bp inserts were removed prior to the subsequent data 
analyses. The Nexalign program (http://genome.gsc.riken.
jp/osc/english/dataresource/) was used to align reads to 
rRNA (NCBI, U133169) and hairpin and mature miRNAs 
(miRBase, R18) (Vaz et al., 2010). The sequences were 
aligned first for exact matches and then the remaining 
sequences were used to identify matches with up to three 
mismatches as described previously (De Hoon et al., 2010). 
The data were deposited in GEO under accession number 
GSE35442. 
2.3. Real-time qPCR analyses 
RNAs smaller than 200 nt were isolated directly from the 
cells using the miRVana miRNA Isolation Kit according 
to the manufacturer’s instruction (Ambion). cDNA was 
prepared from the small RNAs using the RT2 miRNA cDNA 
Kit (SA Biosciences). qPCR was performed in duplicates 
of three biological replicates (Roche, LightCycler 480). U6 
ncRNA was used for normalization.
2.4. Statistical analyses
Student’s t-test was used to statistically analyze the 
biological replicates in flow cytometry and qPCR analyses. 
P ≤ 0.05 was accepted as statistically significant.
3. Results
3.1. Identification of two Jurkat subpopulations with 
different apoptotic properties
We first performed dose-response (0.5–1024 µM) kinetics 
to determine the optimal drug treatment conditions for 
capturing cells at the apoptotic stage (Annexin V-positive 
and 7-AAD-negative). When Jurkat cells were treated with 
camptothecin for 4 h, apoptosis was observed in direct 
proportion to the dose applied up to 8 µM (Figure 1A). 
Percentage of apoptotic cells did not significantly change 
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and reached a plateau after 8 µM. Apoptosis was observed 
in 41% of the cells in camptothecin-treated group 
compared to 5.5% of the control cells (Figure 1A, P < 0.05). 
The unresponsiveness of some cells to the drug led us 
to hypothesize that Jurkat cells may contain additional 
subpopulations, each of which might have a distinct 
camptothecin-mediated apoptotic property. Thus, we 
increased the concentration of the drug up to 1 mM (128-
fold in excess of the maximum 8 µM concentration). 
Interestingly, over 50% of the camptothecin-treated cells still 
remained relatively resistant to the drug treatment despite 
over 100-fold camptothecin concentrations, suggesting the 
presence of a drug-resistant second subpopulation (Figure 
1A). The apparent difference in the apoptotic response 
could stem either from an uneven exposure of the cells to 
the drug or from intrinsic resistance of a subpopulation 
to the drug. To ensure that the differential apoptotic 
capacity of two subpopulations is not due to uneven drug 
treatment, we sorted the nonapoptotic cells and retreated 
them with the drug. To this end, Jurkat cells were first 
treated with 8 µM camptothecin for 4 h and the Annexin 
V-negative nonapoptotic cells (JAN) were separated from 
the apoptotic cells (JAP) using Annexin V-conjugated 
magnetic beads (Figures 1B–1E). Flow cytometry analysis 
of the sorted cells showed that the sorting efficiency was 
as high as 98.4% (purity > 85%, 95% on average) (Figure 
1E). Retreatment of the nonapoptotic cells (JAN) with 
8 µM camptothecin for 4 h showed that this fraction of 
the cells was indeed intrinsically resistant to induction of 
apoptosis by camptothecin. In the first round of treatment, 
42.4% of the cells underwent apoptosis, while the second 
camptothecin treatment triggered apoptosis in only 
7.4% of the JAN cells (Figure 2, P < 0.05). We concluded 
that there are intrinsic gene expression properties, e.g., 
miRNAs, associated with resistance to the camptothecin-
induced apoptosis in Jurkat T cells apparently composed 
of at least two subpopulations.
To investigate whether each Jurkat subpopulation 
possesses a distinct miRNA expression profile, we 
compared the miRNA expression patterns in 3 replicates 
of each subpopulation. The JNN sample contained the 
Annexin V-negative cells, which were not treated with 
the drug (negative control), whereas the JAN and JAP 
samples contained the Annexin V-negative (intrinsically 
camptothecin-resistant)  and -positive (intrinsically 
camptothecin-susceptible) cells, respectively, which were 
treated with the drug. It should be noted that although the 
majority of the camptothecin-treated cells were Annexin 
V-positive and 7-AAD-negative prior to sorting, they 
shifted to a Annexin V/7-AAD-double positive phenotype 
after sorting. We used the Illumina platform (Fasteris, 
Switzerland) to quantitatively measure the amounts 
of small RNAs in each sample. After the removal of the 
adapter sequences, 91.3% of all reads contained 15–29 bp 
inserts. Based on the size of the inserts, there appeared 
to be two major small RNA populations, one of 22–23 
bp and the other 28 bp, each representing miRNAs and 
tRNA-derived small RNAs, respectively (Figure 3). The 
alignment of the reads to the known RNAs revealed two 
striking points with respect to the small RNA content of 
each sample: 1) The control JNN cells are rich in miRNA, 
which constitutes 60% of small RNAs. The miRNA content 
plummets to 26% and 16% in the camptothecin-treated 
JAN and JAP samples, respectively. 2) The drug treatment 
induces major tRNA fragmentation, constituting up to 
45% of all small RNAs (Figure 3; nt 27–29 region). We did 
not notice a major difference in the proportion of other 
small RNA categories, although there may be differences 
in the expression of individual small RNAs.
3.2. Apoptosis is regulated by differential miRNA 
expression
The alignment of reads to the known miRNAs in miRBase 
(R18) resulted in identification of 184 miRNAs differentially 
expressed among the three samples (Table 1). Our list 
includes the differentially expressed miRNAs, whose 
expression are greater than 10 reads per million (RPM) 
in all three samples. Thus, the number of differentially 
expressed genes could be greater. Camptothecin treatment 
usually suppresses miRNA expression compared to the 
control cells (Table 2: 38 induced miRNAs versus 144 
downregulated miRNAs in the JAN or JAP samples). We 
identified a single miRNA, miR-1246, overexpressed in the 
camptothecin-treated JAN and JAP samples. However, a 
total of 79 miRNAs were downregulated in response to the 
camptothecin treatment. Interestingly, 16 and 30 miRNAs 
were down- and upregulated in the drug-resistant JAP 
sample, respectively, whereas they were equally expressed 
in the drug-sensitive JAP sample. More interestingly, a 
total of 6 miRNAs (let-7b-5p, miR-15a-5p, 324-5p, 128, 
425, and 720) were reciprocally expressed in the drug-
sensitive and resistant cells. To validate our findings 
from deep sequencing, we randomly chose 7 miRNAs for 
validation by real-time qPCR, namely miR-7, 17, 18a, 25, 
26a, 93, and 425. As shown in Figure 4, the qPCR results 
were quite consistent with the deep-sequencing data. 
4. Discussion
The balance between proliferation and apoptosis is 
important for the overall cellular homeostasis. Apoptosis 
is particularly important in modulating the fate of 
immune cells, including T cells. Microarray and deep-
sequencing studies have been instrumental in  identifying 
several miRNAs involved in cell proliferation or apoptosis 
(Subramanian and Steer, 2010). However, these studies 
were mainly conducted with heterogeneous cancerous 
tissues in which the apoptotic states of the cells were not 
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synchronized. Thus, we used the Jurkat cell line and the 
universal apoptosis inducer camptothecin to identify the 
miRNAs involved in apoptosis. The apoptotic cells were 
identified by marking the cells in which phosphatidylserine 
was exposed to the cell surface, which is readily detected 
by Annexin V labeling. Sorting cells based on their 
Annexin-V labeling allowed us to obtain the miRNA 
expression profile of a purely apoptotic cell population 
(Annexin V/7-AAD-double positive).
MiR-14 and bantam were the first miRNAs shown 
to have apoptotic function in Drosophila (Brennecke 
et al., 2003; Xu et al., 2003). Studies on various cancer 
cells showed a prominent p53-mediated regulation of 
miRNAs, particularly the miR-34 family, miR-215 and 
192, with proapoptotic capacity (He et al., 2007; Georges 
et al., 2008). However, we did not detect any differential 
expression of these miRNAs in our study. Let-7 and miR-
15/16 were also reported to be associated with apoptosis 
(Ghodgaonkar et al., 2009). MiR-16-1 and let-7d, -7g, and 
-7i were suppressed in the camptothecin-resistant JAN 
cells. MiR-16-2 and miR-15a, on the other hand, were 
slightly upregulated. These miRNAs were suppressed in 
 
A  
 
 
 
 
 
           B     C    D    E  
 
 
 
 
 
 
 
Figure 1. Dose response and identification of apoptotic cells by flow cytometry. A) Dose kinetics of camptothecin. Jurkat cells 
were treated with a range of camptothecin (0.5–1024 µM) for 4 h and the apoptotic cells were determined with Annexin V/7-AAD 
labeling. B–E) Enrichment of apoptotic cells with magnetic bead separation. Jurkat cells were treated with 8 µM camptothecin for 4 
h and the apoptotic cells were sorted using an Annexin V magnetic bead separation kit. The apoptosis rate of the following samples 
was determined by flow cytometry: B) control, untreated cells (JNN); C) camptothecin-treated cells, D) camptothecin-treated and 
magnetic bead-sorted Annexin V-negative cells (JAN); E) camptothecin-treated, magnetic bead-sorted Annexin V-positive cells 
(JAP). It is important to note that the cells became Annexin V/7-AAD-double positive following the sorting. 
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camptothecin-treated Jurkat cells. The miR-17-92 cluster, 
which encodes miR-17-3p, -17-5p, -18a, -19a, -20a, -19b, 
and 92, is one of the well-established miRNA clusters with 
antiapoptotic activity (He et al., 2007; Georges et al., 2008). 
We observed nearly 4- to 5-fold downregulation of these 
miRNAs in camptothecin-treated Jurkat cells, parallel to the 
published results. MiR-125 and -128, which are reported to 
be antiapoptotic miRNAs in Jurkat cells (Yamado et al., 2014; 
Zhou et al., 2014), are downregulated in the camptothecin-
treated cells, as expected. MiR-143, which is expressed at an 
extremely low level in cancer cell lines compared to normal 
tissues, is involved in Fas-mediated apoptosis in Jurkat cells 
(Akao et al., 2009). Accordingly, this particular miRNA was 
nearly undetectable in Jurkat cells. However, its expression 
did not change in response to the camptothecin treatment.
Our study revealed the involvement of additional 
miRNAs that may modulate apoptosis in human Jurkat 
T cells (Table 1). The most striking dysregulations were 
detected in the expression of miR-17*, -128, -140, -142, 
-161, -186, -766, and-1268. Although these miRNAs are 
dysregulated in camptothecin-treated Jurkat T cells, we 
cannot unequivocally state that they are directly involved 
in modulating apoptotic pathways. It is possible that they 
may be associated with response to drug treatment, such 
as drug efflux. Further studies are required to determine 
their involvement, if any, in apoptosis and related signaling 
pathways.
Although camptothecin is known to be a potent 
apoptosis inducer, a portion of the cells were unresponsive 
to the drug despite over 100-fold increase in the drug 
concentration (Figures 1A and 1C). This observation 
was consistent with previous reports that there may be 
phenotypic and genotypic heterogeneity in clonal cell 
populations (Stockholm et al., 2007; Walling and Shepard, 
2012). To validate the cellular heterogeneity in the Jurkat 
cell line, we sorted the Annexin-V-positive cells (JAP) from 
the Annexin-V-negative cells (JAN) following the initial 
drug treatment and retreated the Annexin-V-negative, 
apoptosis-resistant cells with camptothecin. Although 
the inclusion of the Annexin-V-positive fraction of the 
untreated control cells (JNP) would provide valuable insight 
into the potential role of miRNAs in natural or accidental 
death (i.e. drug-independent), the number of these cells 
was always insufficient for downstream experiments. Thus, 
we focused on the drug-treated samples. Interestingly, 
some of the drug-tested cells were intrinsically resistant to 
the drug (Figure 1C and Figure 2). To investigate whether 
the differential apoptotic response of each subpopulation 
is associated with the differential miRNA expression, we 
subjected the total RNAs from each subpopulation to deep 
sequencing using the untreated cells as control. There were 
79 miRNAs commonly downregulated in both populations 
(Table 2). Quite interestingly, although 16 and 30 miRNAs 
were down- and upregulated in the drug-resistant JAN 
sample, respectively, they were equally expressed in the 
drug-sensitive JAP sample. More interestingly, a total of 
6 miRNAs (let-7b-5p, miR-15a-5p, 324-5p, 128, 425, and 
720) were reciprocally expressed in the drug-sensitive JAP 
and resistant JAN subpopulations (Table 1). Pending the 
direct demonstration of their role in cell-specific response 
to drugs, this observation suggests that the miRNA 
expression data obtained from drug treatments should be 
carefully interpreted if the cells of the desired phenotype 
are not sorted from the other cells. The presence of cells 
with undesired phenotypes may introduce noise that may 
P<0.05
Figure 2. Two subpopulations of Jurkat cells with different 
camptothecin-mediated apoptotic capacity. Following the 
magnetic bead separation of camptothecin-treated and magnetic 
bead-sorted Annexin V-negative cells (Figure 1D, JAN cells), 
these cells were retreated with camptothecin for 4 h. Apoptosis 
was measured with Annexin V/7-AAD labeling. 1st CPT: Cells 
treated with camptothecin once; 2nd CPT (JAN): sorted cells that 
were retreated with camptothecin. 
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Figure 3. Small RNA profiles of camptothecin-treated Jurkat 
cells. The 15–29 bp fragments were sorted based on their size 
and plotted as percentage. JNN: Small RNA population in the 
drug-free control cells; JAP: camptothecin-treated and Annexin 
V-positive cells; JAN: camptothecin-treated and Annexin 
V-negative cells.
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Table 1. A list of miRNAs deregulated in camptothecin-treated Jurkat cells. The cloning frequency of miRNAs was calculated as reads 
per million (RPM) following the removal of the adapter sequences. The miRNAs with a cloning frequency of 10 RPM in all three samples 
were used in calculations. The fold of expression is presented in a log ratio. JNN: Drug-free control cells; JAN: Annexin V-negative 
fraction of drug-treated cells; JAP: Annexin V-positive fraction of drug-treated cells. 
Upregulated in JAN Suppressed in JAN vs JNN
miRNA JAN/JNN JAP/JNN JAP/JAN miRNA JAN/JNN JAP/JNN JAP/JAN
hsa-miR-128 4.82 –2.94 –7.75 hsa-miR-19b-3p –1.63 –4.34 –2.71
hsa-miR-17-3p 7.14 0.51 –6.62 hsa-miR-19a-3p –1.73 –4.31 –2.59
hsa-miR-720 1.74 –3.42 –5.15 hsa-miR-17-5p –1.59 –3.87 –2.28
hsa-miR-7-5p 3.53 –0.52 –4.05 hsa-miR-20b-5p –1.10 –3.23 –2.13
hsa-miR-1268b 3.79 –0.26 –4.05 hsa-miR-210 –1.91 –3.97 –2.06
hsa-miR-1268a 3.77 –0.26 –4.04 hsa-miR-374a-5p –1.09 –2.93 –1.84
hsa-miR-25-3p 3.49 –0.41 –3.90 hsa-miR-320a –2.57 –4.29 –1.72
hsa-let-7b-5p 1.60 –2.19 –3.79 hsa-miR-29b-3p –5.01 –6.44 –1.43
hsa-miR-324-5p 1.87 –1.85 –3.72 hsa-let-7d-5p –1.95 –3.29 –1.34
hsa-miR-106b-3p 2.76 –0.86 –3.62 hsa-miR-185-5p –1.27 –2.34 –1.08
hsa-miR-101-3p 2.62 –0.66 –3.28 hsa-miR-484 –1.83 –2.77 –0.94
hsa-miR-221-3p 3.17 –0.07 –3.23 hsa-miR-150-3p –1.02 –1.86 –0.83
hsa-miR-331-3p 2.85 –0.36 –3.21 hsa-miR-20b-3p –1.34 –2.14 –0.80
hsa-miR-15a-5p 1.88 –1.09 –2.97 hsa-miR-106a-5p –2.50 –3.24 –0.74
hsa-miR-28-3p 1.75 –0.95 –2.70 hsa-miR-153 –1.56 –2.22 –0.66
hsa-let-7d-3p 1.52 –0.99 –2.51 hsa-miR-542-5p –1.77 –2.43 –0.65
hsa-miR-16-2-3p 1.62 –0.68 –2.30 hsa-miR-1301 –2.37 –3.01 –0.64
hsa-miR-21-5p 1.63 –0.63 –2.26 hsa-miR-148a-5p –1.35 –1.87 –0.53
hsa-miR-3613-5p 2.02 –0.21 –2.23 hsa-miR-454-3p –1.35 –1.85 –0.49
hsa-miR-181d 1.87 –0.33 –2.20 hsa-miR-26b-5p –3.17 –3.58 –0.41
hsa-miR-362-5p 2.13 –0.07 –2.20 hsa-miR-181b-3p –1.20 –1.54 –0.34
hsa-miR-548d-5p 1.66 –0.50 –2.16 hsa-miR-191-5p –4.24 –4.57 –0.33
hsa-miR-301a-5p 1.54 –0.37 –1.92 hsa-miR-301b –1.86 –2.17 –0.31
hsa-miR-186-3p 1.68 –0.17 –1.84 hsa-miR-20a-5p –3.54 –3.83 –0.30
hsa-miR-1307-3p 1.08 –0.63 –1.71 hsa-miR-222-3p –1.69 –1.93 –0.24
hsa-miR-671-3p 1.07 –0.54 –1.61 hsa-miR-30c-1-3p –2.58 –2.81 –0.22
hsa-miR-32-3p 1.30 –0.27 –1.57 hsa-miR-590-3p –1.19 –1.41 –0.21
hsa-miR-378d 1.32 –0.03 –1.35 hsa-miR-183-5p –1.08 –1.29 –0.21
hsa-miR-589-5p 1.01 –0.30 –1.31 hsa-miR-342-5p –1.13 –1.30 –0.17
hsa-miR-4677-3p 1.13 –0.16 –1.28 hsa-miR-545-5p –1.03 –1.19 –0.17
hsa-miR-548w 1.35 0.09 –1.25 hsa-miR-625-3p –1.34 –1.51 –0.16
hsa-miR-378c 1.14 –0.09 –1.23 hsa-miR-30b-3p –2.59 –2.71 –0.12
hsa-miR-29b-1-5p 1.06 0.00 –1.06 hsa-miR-146b-5p –1.84 –1.92 –0.07
hsa-miR-193a-5p 1.75 0.69 –1.06 hsa-miR-4454 –1.13 –1.19 –0.06
hsa-miR-424-3p 1.20 0.21 –0.99 hsa-miR-503 –1.61 –1.65 –0.04
hsa-miR-1246 1.86 2.73 0.87 hsa-miR-99b-5p –1.13 –1.14 –0.01
hsa-miR-106a-3p –1.04 –1.04 0.00
hsa-miR-1285-3p –1.39 –1.39 0.00
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Equal in JAN vs. JNN hsa-miR-331-5p –1.78 –1.78 0.00
miRNA JAN/JNN JAP/JNN JAP/JAN hsa-miR-28-5p –1.12 –1.08 0.03
hsa-miR-92a-1-5p –0.87 –4.54 –3.67 hsa-miR-19b-1-5p –2.85 –2.80 0.05
hsa-miR-26a-5p –0.35 –3.69 –3.35 hsa-miR-1277-3p –3.02 –2.97 0.05
hsa-miR-18a-5p –0.41 –3.62 –3.21 hsa-miR-96-5p –2.39 –2.34 0.05
hsa-miR-301a-3p 0.86 –2.17 –3.03 hsa-miR-744-3p –1.24 –1.17 0.07
hsa-miR-125a-5p 0.69 –2.26 –2.94 hsa-miR-29a-3p –3.01 –2.94 0.07
hsa-miR-18b-5p 0.59 –2.15 –2.74 hsa-miR-532-5p –1.20 –1.12 0.08
hsa-let-7a-5p 0.33 –2.18 –2.52 hsa-miR-26b-3p –1.28 –1.19 0.10
hsa-miR-296-3p –0.01 –2.48 –2.47 hsa-let-7g-3p –1.98 –1.88 0.11
hsa-miR-27b-3p 0.71 –1.74 –2.45 hsa-miR-130b-3p –4.70 –4.58 0.12
hsa-miR-148a-3p –0.59 –2.86 –2.27 hsa-miR-140-3p –1.46 –1.33 0.13
hsa-miR-374b-5p 0.44 –1.81 –2.26 hsa-miR-16-1-3p –2.84 –2.69 0.15
hsa-miR-92a-3p 0.53 –1.68 –2.21 hsa-miR-151a-5p –4.74 –4.55 0.19
hsa-miR-744-5p 0.46 –1.68 –2.14 hsa-miR-424-5p –4.79 –4.59 0.20
hsa-miR-150-5p 0.61 –1.43 –2.04 hsa-miR-223-5p –1.71 –1.50 0.21
hsa-miR-106b-5p –0.40 –2.38 –1.98 hsa-miR-30b-5p –2.58 –2.34 0.24
hsa-miR-191-3p –0.03 –1.99 –1.96 hsa-let-7i-3p –2.75 –2.49 0.25
hsa-miR-223-3p 0.50 –1.42 –1.92 hsa-miR-197-3p –2.08 –1.80 0.28
hsa-miR-18a-3p –0.35 –2.11 –1.76 hsa-let-7i-5p –1.92 –1.62 0.30
hsa-miR-92b-3p 0.20 –1.54 –1.75 hsa-miR-30d-3p –1.37 –1.07 0.30
hsa-miR-29c-3p –0.66 –2.41 –1.74 hsa-miR-1277-5p –2.22 –1.88 0.34
hsa-miR-181a-3p –0.36 –1.89 –1.52 hsa-miR-194-5p –2.13 –1.76 0.38
hsa-let-7e-5p –0.72 –2.24 –1.52 hsa-miR-627 –2.09 –1.72 0.38
hsa-miR-219-1-3p 0.53 –0.93 –1.46 hsa-miR-200c-3p –2.41 –1.96 0.45
hsa-miR-27a-3p –0.14 –1.59 –1.45 hsa-miR-500a-5p –1.05 –0.57 0.48
hsa-let-7c 0.22 –1.21 –1.43 hsa-miR-93-3p –1.42 –0.90 0.52
hsa-miR-98 –0.21 –1.63 –1.42 hsa-miR-146a-5p –3.25 –2.72 0.53
hsa-miR-942 0.24 –1.17 –1.41 hsa-miR-320b –1.52 –0.94 0.57
hsa-miR-7-1-3p 0.12 –1.25 –1.38 hsa-miR-9-3p –1.39 –0.73 0.66
hsa-let-7f-5p 0.10 –1.19 –1.29 hsa-miR-374a-3p –2.08 –1.42 0.66
hsa-miR-181a-2-3p 0.31 –0.98 –1.28 hsa-miR-320c –1.59 –0.88 0.71
hsa-miR-652-3p 0.44 –0.78 –1.22 hsa-miR-450b-5p –1.78 –1.04 0.74
hsa-miR-548b-5p 0.90 –0.31 –1.21 hsa-miR-320d –1.04 –0.24 0.79
hsa-miR-9-5p 0.57 –0.61 –1.18 hsa-miR-542-3p –1.44 –0.62 0.83
hsa-miR-93-5p 0.09 –1.08 –1.17 hsa-miR-629-3p –1.24 –0.38 0.86
hsa-miR-760 0.81 –0.33 –1.14 hsa-miR-148b-3p –3.28 –2.36 0.92
hsa-miR-184 0.96 –0.15 –1.12 hsa-miR-340-3p –1.36 –0.44 0.93
hsa-miR-151a-3p –0.30 –1.32 –1.01 hsa-miR-339-5p –1.34 –0.27 1.07
hsa-miR-95 0.01 –1.00 –1.01 hsa-miR-345-5p –1.41 –0.30 1.11
hsa-miR-152 0.12 –0.88 –1.01 hsa-miR-342-3p –2.72 –1.60 1.11
Table 1. (Continued).
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interfere with the accurate assessment of the phenotype-
specific miRNA expression profiles.
We then carried out gene ontology analyses using 
DIANA to examine which biological processes could be 
affected by the miRNAs inversely expressed in the JAN 
and JAP samples (Vlachos et al., 2015). MiR-720 was 
shown to originate from a tRNA (Schopman et al., 2010). 
Thus, we excluded this miRNA in our gene ontology 
analyses. Of the other five miRNAs, let-7b-5p targets 
modulate the cell cycle, chronic myeloid leukemia, 
p53 signaling, hippo signaling, and thyroid hormone 
signaling. MiR-15 targets are involved in the cell cycle, 
pathways in cancer, and several signaling pathways such 
as p53, TGF-beta, hippo, and thyroid hormone. MiR-
128 target genes are interesting in that they typically 
modulate extracellular matrix organization, focal 
adhesion, or proteoglycan in cancer. MiR-324 has binding 
sites on mRNAs whose biological functions include 
hippo signaling, adherence junction, and miRNAs in 
cancer while miR-425 target genes function in N-glycan 
biosynthesis, adherence junction, thyroid hormone, and 
hippo signaling. From these analyses, it is possible to 
state that the target genes of these five miRNAs appear 
to modulate common biological processes, such as the 
cell cycle, focal adhesion, and several key signaling 
pathways, such as p53, hippo, and thyroid hormones. 
Interestingly, recent studies demonstrate, for example, 
the importance of cell-to-cell variation in p53 expression 
in inducing apoptosis (Paek et al., 2016). Further studies 
hsa-miR-501-3p –0.40 –1.26 –0.86 hsa-miR-126-3p –1.96 –0.78 1.18
hsa-miR-27b-5p –0.29 –1.07 –0.78 hsa-miR-193b-3p –2.05 –0.82 1.23
hsa-miR-15b-3p –0.55 –1.33 –0.77 hsa-miR-363-3p –2.82 –1.55 1.27
hsa-miR-30e-3p –0.40 –1.13 –0.73 hsa-miR-361-5p –6.52 –5.24 1.28
hsa-miR-203 –0.36 –1.04 –0.69 hsa-miR-126-5p –2.77 –1.42 1.36
hsa-miR-340-5p –0.82 –1.34 –0.52 hsa-miR-769-5p –3.28 –1.87 1.41
hsa-miR-196a-5p –0.99 –1.39 –0.40 hsa-miR-140-5p –6.36 –4.74 1.61
hsa-miR-625-5p –0.88 –1.19 –0.31 hsa-miR-30c-5p –4.80 –2.90 1.90
hsa-miR-580 –0.85 –1.13 –0.29 hsa-miR-455-3p –1.37 0.66 2.03
hsa-miR-454-5p –0.93 –1.01 –0.08 hsa-let-7g-5p –6.14 –3.78 2.37
hsa-miR-1292 –1.00 –1.02 –0.02 hsa-miR-186-5p –5.45 –2.80 2.65
hsa-miR-1248 0.06 1.03 0.97 hsa-miR-24-3p –3.48 –0.81 2.67
hsa-miR-181a-5p –0.81 0.31 1.13 hsa-miR-142-5p –6.58 –3.89 2.70
hsa-miR-32-5p –3.12 –0.11 3.01
hsa-miR-142-3p –4.60 –1.08 3.52
hsa-miR-766-3p –4.79 –1.05 3.74
hsa-miR-425-5p –2.48 1.74 4.22
Table 1. (Continued).
Table 2. A summary of differentially expressed miRNAs and 
qPCR validation. The dysregulated miRNAs from Table 1 
are summarized. JNN: Control Jurkat cells not treated with 
camptothecin; JAN and JAP: Annexin V-negative and -positive 
populations of camptothecin-treated cells, respectively; +: 
induced miRNAs; -: suppressed miRNAs; =: equally expressed 
miRNAs.
JAN/JNN JAN/JNN JAP/JAN #
- - = 57
= - - 30
+ = - 29
- - + 12
= - = 11
- - - 10
- = = 9
= = - 9
- = + 7
+ - - 5
+ + = 1
+ = = 1
- + + 1
= + = 1
= = + 1
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would be required, however, to directly show whether 
these biological processes modulate cellular heterogeneity 
through the differentially expressed miRNAs reported in 
our study.
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Figure 4. qPCR validation of differentially expressed miRNAs. cDNA was prepared from a fraction of the total RNAs used in deep 
sequencing analysis using the RT2 miRNA cDNA Kit (SA Biosciences). qPCR was performed in duplicates of three biological replicates. 
U6 small RNA was used for normalization. ±: Standard deviation. qPCR results are graphed side by side with the deep-sequencing data 
for visual comparison.
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